Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TAR-200 plus cetrelimab versus concurrent chemoradiotherapy in muscle-invasive bladder cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urinary Bladder Neoplasms

Drugs mentioned

• Cetrelimab
• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urinary Bladder Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING